- Home
- WATT vs PTIX Comparison
WATT vs PTIX Comparison
Compare WATT & PTIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WATT
- PTIX
- Stock Information
- Founded
- WATT 2012
- PTIX 1994
- Country
- WATT United States
- PTIX United States
- Employees
- WATT N/A
- PTIX N/A
- Industry
- WATT Radio And Television Broadcasting And Communications Equipment
- PTIX Biotechnology: Pharmaceutical Preparations
- Sector
- WATT Technology
- PTIX Health Care
- Exchange
- WATT Nasdaq
- PTIX Nasdaq
- Market Cap
- WATT 3.9M
- PTIX 3.9M
- IPO Year
- WATT 2014
- PTIX 2016
- Fundamental
- Price
- WATT $0.47
- PTIX $0.64
- Analyst Decision
- WATT Strong Buy
- PTIX
- Analyst Count
- WATT 2
- PTIX 0
- Target Price
- WATT $2.25
- PTIX N/A
- AVG Volume (30 Days)
- WATT 201.1K
- PTIX 239.9K
- Earning Date
- WATT 11-12-2024
- PTIX 11-14-2024
- Dividend Yield
- WATT N/A
- PTIX N/A
- EPS Growth
- WATT N/A
- PTIX N/A
- EPS
- WATT N/A
- PTIX N/A
- Revenue
- WATT $431,184.00
- PTIX N/A
- Revenue This Year
- WATT $95.75
- PTIX N/A
- Revenue Next Year
- WATT $834.07
- PTIX N/A
- P/E Ratio
- WATT N/A
- PTIX N/A
- Revenue Growth
- WATT N/A
- PTIX N/A
- 52 Week Low
- WATT $0.45
- PTIX $0.49
- 52 Week High
- WATT $2.75
- PTIX $1.87
- Technical
- Relative Strength Index (RSI)
- WATT 32.37
- PTIX 50.85
- Support Level
- WATT $0.45
- PTIX $0.54
- Resistance Level
- WATT $0.58
- PTIX $0.64
- Average True Range (ATR)
- WATT 0.04
- PTIX 0.14
- MACD
- WATT -0.01
- PTIX -0.01
- Stochastic Oscillator
- WATT 12.96
- PTIX 20.97
About WATT Energous Corporation
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. Its products include Transmitter IC & Module, Receivers IC, Transmitter System and other tools.
About PTIX Protagenic Therapeutics Inc.
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.